It depends on the standard you follow. As of September 2026, Arcutis Biotherapeutics, Inc. (ARQT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.11% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.37% / 30% · Interest income / Revenue 1.80% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.11% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.37% / 33% · Receivables / Mkt Cap (36m) 4.87% / 49% · Interest income / Revenue 1.80% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 3.11% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.37% / 33.33% · Receivables / Mkt Cap (24m) 4.87% / 33.33% · Interest income / Revenue 1.80% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 17.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 49.5% / 33.33% · Receivables / Avg Assets (4Q) 32.4% / 33.33% · Interest income / Revenue 1.80% / 5% | Fail |
| FTSE | Debt / Total Assets 20.9% / 33.33% · (Cash+ST Inv) / Total Assets 49.5% / 33.33% · (Cash+Recv) / Total Assets 82.1% / 33.33% · Interest income / Revenue 1.80% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Arcutis Biotherapeutics, Inc. (ARQT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Arcutis Biotherapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.80% of each dividend: Arcutis Biotherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Arcutis Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.15, Arcutis Biotherapeutics, Inc. trades at 116.7x trailing earnings, 6.7x sales and 14.6x book value, with an EV/EBITDA of 78.4. Over the last twelve months it generated about $509M of revenue and $29M of net income. It runs a gross margin of 91.2%, an operating margin of 6.9% and a net margin of 5.9%. It shows return on equity of 14.2%, return on invested capital of 9.5% and a free cash flow yield of 1.7%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 2.92. Over the past 52 weeks the share price ranged from $19.30 to $34.80, with a beta of 1.63.
Arcutis Biotherapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.